Status:
COMPLETED
The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Society for Pediatric Dermatology
Johnson & Johnson
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
6-17 years
Phase:
PHASE4
Brief Summary
Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, t...
Detailed Description
Background Atopic dermatitis (AD) is a chronic condition of pruritus and eczematous lesions that affects 15-20% of children. It commonly presents early in life and is associated with other atopic dise...
Eligibility Criteria
Inclusion
- 6 months to 17 years of age
- Moderate to severe atopic dermatitis
Exclusion
- Use of cephalexin or other antibiotic in last 6 weeks
- Allergy to cephalosporins
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00179959
Start Date
September 1 2005
End Date
March 1 2011
Last Update
December 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Memorial Hospital
Chicago, Illinois, United States, 60614